Diaverum develops breakthrough AI model to deliver step-change in Vascular Access (VA) thrombosis prevention
Diaverum, a leading global renal care service provider, has developed an artificial intelligence model to support the company’s physicians and nurses predict with a high degree of accuracy, episodes of vascular access thrombosis among haemodialysed patients. Simulations using Diaverum’s historical patient data predicted an average of 75% of actual cases that were not detected by best-in-class clinical assessments and monitoring systems.
Vascular Access (VA) thrombosis is a major factor of suffering and increased mortality for chronic haemodialysis patients, with incidence ranging between 0.11 to 0.5 episodes per patient every year. It accounts for a significant increase of the total cost of care for these patients, contributing to the unsustainable trajectory of growing expenditure and disease burden impacting national healthcare systems around the world.
Diaverum’s VA model follows the principles of human-centric, explainable, and responsible AI. It uses personalised input variables comprising dialysis treatment data, lab tests results and demographics, predicting if the patient will suffer from a thrombotic event one week before the episode takes place. The AI prediction is presented to the nephrologists together with a set of explainable insights, empowering them to offer preventive personalised care to maintain the patient’s vascular access survival.
The new VA AI model is integrated into the company’s digitalised clinical workflows and interfaces with its digital infrastructure, including its proprietary renal information platform, d.CARE, and Treatment Guidance System (TGS).
Starting with its operations in Saudi Arabia, Portugal and Spain, which care for approximately 12.000 renal patients, the company’s ambition is to roll out the model to its entire network of 452 clinics in 24 countries, over the next 18 months.
To learn more about the company’s digital transformation and VA AI model, join a live announcement webinar hosted by Diaverum’s CEO, Dimitris Moulavasilis, and CMO, Fernando Macário.